David A. Lowe, PhD, leads the Parkinson’s Disease Therapeutics and Imaging programs at AC Immune. Previously, Dr. Lowe was the chief scientific officer (CSO) at PsychoGenics Inc.; CSO at Memory Pharmaceuticals (acquired by Roche); executive vice president and CSO at Fidelity Biosciences Group in Boston; president, CEO and director of Envivo Pharmaceuticals (now Forum Pharmaceuticals); vice president and therapeutic area head at Roche Bioscience in Palo Alto; vice president and global therapeutic area head at Bayer AG.; and head of CNS Biology and deputy head of CNS Research at Sandoz Ltd (now Novartis).
Dr. Lowe has more than 35 years of experience in pharmaceutical drug discovery and product development, with an established track record of generating diverse clinical candidates. He received his PhD in neurobiology from the University of Leeds, UK and has published over 60 papers in peer reviewed journals.